Navigation Links
NIST, NCI, SAIC partner on new method for detecting HER2 breast cancer
Date:2/19/2008

Generations of mothers have served up chicken soup to remedy the common cold, but now the therapeutic fowl may find use in diagnosis as well. Researchers at the National Institute of Standards and Technology (NIST), the National Cancer Institute (NCI) and the scientific research firm SAIC recently showed how chicken antibodies may one day improve the detection of an aggressive form of breast cancer.

HER2 is one of a family of genes that help regulate the growth and proliferation of human cells. Normal cells have two copies of HER2, but about 20 to 25 percent of breast cancers have multiple copies of the gene, resulting in the overproduction of a HER2-encoded protein (called HER2) that stimulates tumors to be particularly fast growing and difficult to treat in a subset of breast cancer patients.

Patients with that form of breast cancerabout 40,000 women in the United States annuallycan be treated with a monoclonal antibody called trastuzumab that targets and inhibits the growth of tumor cells with higher-than-normal levels of the HER2 protein. But because the treatment can have adverse side effects, its important to screen for those patients who would benefit from it by testing them for one or both of the two relevant biomarkers: the amplified HER2 gene or its overexpressed HER2 protein. Unfortunately, the existing tests for these biomarkers can yield a significant number of false positivesas many as 23 percent of patients in one 2006 clinical studyresulting in some women getting a somewhat risky and expensive treatment that cant help them.

In a paper in the International Journal of Cancer,* the NIST-NCI-SAIC research team found that chicken immunoglobulin Y (IgY) antibody created against the HER2 protein could be tagged with quantum dot (tiny, intense and tunable sources of colorful light) to more reliably detect the HER2 biomarker than the existing diagnostic tests using mammalian antibodies tagged with conventional fluorescent dyes. Overall, the improvement in sensitivity to the HER2 biomarker was about 40-50 percent.

The increased sensitivity of the HER2 quantum dot-based quantitative bioimaging system stems from the broad genetic differences between avian and human species. The chicken IgY antibody to HER2 reacts strongly with the target protein while ignoring other human proteins that can interfere with current diagnostic tests.

Other advantages of the novel NIST-NCI-SAIC system include faster and larger-scale production of the antibodies and a more reliable quantitative measure of HER2 biomarker level, in part because the quantum dot tags will stay bright and detectable while fluorescent dyes fade over time.


'/>"/>

Contact: Michael E. Newman
michael.newman@nist.gov
301-975-3025
National Institute of Standards and Technology (NIST)
Source:Eurekalert  

Related medicine news :

1. 24 Hour Fitness Partners With Derek Jeter to Launch Signature Sports Clubs in New York City
2. The Leukemia & Lymphoma Society and the Nations Triathlon Announce New Partnership
3. WeissComm Partners Names Tom Jones Managing Director to Deepen Global Product Communications Offering
4. Paine & Partners, LLC Announces Sale of Byram Healthcare to OPG Groep N.V.
5. Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Have Been Filed Against American Dental Partners, Inc.
6. CryoCor to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
7. Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners
8. DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference
9. Michigan-Based Businesses Partner to Increase Dental Coverage Access for Medicare Beneficiaries
10. AIDS Healthcare Foundation and NCHADS Partnership Adds 8th Cambodian AIDS Treatment Center in Kirivong
11. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIST, NCI, SAIC partner on new method for detecting HER2 breast cancer
(Date:3/30/2017)... ... March 30, 2017 , ... According to the American Society of Plastic Surgeons ... among the top 5 most popular minimally-invasive cosmetic procedures in the country. With summer ... performed over the next 8-10 weeks. For anyone considering a hair removal procedure, there ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a leader in training ... Readmissions Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, MSN, ... strategies to prevent readmissions in light of the most recent programs at the ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... and women’s professional squash, announced it has enlisted New York City-based sports and ... agency will develop and procure sponsorship opportunities for the Professional Squash Association (PSA), ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Novartis announced today ... has accepted the company,s Biologics License Application (BLA) ... an investigational chimeric antigen receptor T cell (CAR-T) ... young adult patients with B-cell acute lymphoblastic leukemia ... Novartis for a CAR-T. The priority review designation ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "South ... & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected to ... Untapped Proton Therapy Market for South Korea was ... Proton Therapy plays an important role in delivering comprehensive cancer care to ...
(Date:3/29/2017)... 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical technology ... medical devices for pain management, stroke rehabilitation, cardiac monitoring ... the Company,s 2016 full-year investor webcast on Monday, April 3, ... The Company expects to file its 2016 full year ... ...
Breaking Medicine Technology: